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SHORT REPORT Open Access
TLR-4 ligation of dendritic cells is sufficient to
drive pathogenic T cell function in experimental
autoimmune encephalomyelitis
Richard J Mellanby1, Helen Cambrook1, Darryl G Turner1, Richard A O’Connor1, Melanie D Leech1,
Florian C Kurschus2, Andrew S MacDonald3, Bernd Arnold4 and Stephen M Anderton1*
Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) depends on the initial activation of CD4+ T cells
responsive to myelin autoantigens. The key antigen presenting cell (APC) population that drives the activation of
naïve T cells most efficiently is the dendritic cell (DC). As such, we should be able to trigger EAE by transfer of DC
that can present the relevant autoantigen(s). Despite some sporadic reports, however, models of DC-driven EAE
have not been widely adopted. We sought to test the feasibility of this approach and whether activation of the
DC by toll-like receptor (TLR)-4 ligation was a sufficient stimulus to drive EAE.
Findings: Host mice were seeded with myelin basic protein (MBP)-reactive CD4+ T cells and then were injected
with DC that could present the relevant MBP peptide which had been exposed to lipopolysaccharide as a TLR-4
agonist. We found that this approach induced robust clinical signs of EAE.
Conclusions: DC are sufficient as APC to effectively drive the differentiation of naïve myelin-responsive T cells into
autoaggressive effector T cells. TLR-4-stimulation can activate the DC sufficiently to deliver the signals required to
drive the pathogenic function of the T cell. These models will allow the dissection of the molecular requirements of
the initial DC-T cell interaction in the lymphoid organs that ultimately leads to autoimmune pathology in the
central nervous system.
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Findings
The clinical manifestation of experimental autoimmune
encephalomyelitis (EAE) depends on the initial activa-
tion of CD4+ T cells responsive to myelin autoantigens
and their differentiation into autoaggressive effector T
cells which, when re-isolated from the inflamed central
nervous system (CNS) can produce a range of pro-
inflammatory cytokines including IFN-γ, IL-17, TNF-α
and granulocyte-macrophage colony-stimulating factor
(GM-CSF) [1]. The immunological consensus is that the
key antigen presenting cell (APC) population, capable of
driving the activation of naïve T cells most efficiently, is
the dendritic cell (DC) [2]. As such, many studies have
shown that inoculation of mice with antigen-loaded DC
can substitute for active immunization with the antigen
in adjuvant to provoke a T cell response. Achieving this
as a robust experimental option for the induction of
EAE would allow us to probe the molecular require-
ments for the initial DC-T cell interaction in the lymph-
oid organs that ultimately leads to autoimmune
pathology in the CNS. It is notable, however, that despite
some sporadic reports [3-5], this has not as yet been
achieved. Classically, the induction of EAE requires the
use of complete Freund’s adjuvant (CFA), which contains
a range of mycobacterial-derived molecules to trigger
DC activation through their pattern-recognition recep-
tors (PRRs). The most common means of activating DC
prior to their use for cellular immunization is to use the
toll-like receptor (TLR)-4 agonist lipopolysaccharide
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(LPS). Thus, one possible reason for the lack of a robust
DC-driven model of EAE may be that LPS-activated DC
cannot provide all of the signals to the naïve myelin-
response T cells to engender strong autoaggressive
function.
To formally test this possibility, we sought to induce
EAE using bone marrow-derived DC (BMDC) that had
received only the TLR4-signal in vitro, by activation with
LPS. To maximize our chances of success we first sought
to obviate two possible confounding issues – the size of
the naïve myelin-responsive repertoire and the ability of
the DC to present the autoantigen. We therefore started
by developing a transgenic two-cell transfer model. We
have previously reported that C57BL/6xB10.PL mice are
resistant to EAE induction using the Ac1-9 peptide of
myelin basic protein (MBP), unless they are first seeded
with a cohort of naïve MBP-responsive T cells derived
from the Tg4 T cell receptor (TCR) transgenic mouse
[6]. This approach therefore allowed us to control the
size of the Ac1-9-responsive T cell repertoire. To remove
the possibility that BMDC may for some reason fail to
present the Ac1-9 peptide efficiently, we made use of a
second transgenic line, the AMK35 mouse, in which
major histocompatibility molecule (MHC) class II-
expressing cells constitutively express the Ac1-9 peptide,
covalently bound to the AU molecule [7].
BMDC generated from AMK35 mice showed elevated
expression of Au, CD80 and CD86 after overnight expos-
ure to LPS (Figure 1A) and supernatants from these cul-
tures contained elevated levels of pro-inflammatory
cytokines (Figure 1B), notably IL-1β, IL-6 and IL-23,
each of which has been described as being required for
EAE development using gene-deficient mice [8-10].
These LPS-activated AMK35 DC also efficiently induced
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Figure 1 MBP loaded BMDC can prime MBP responsive T cells.
BMDC were generated in the presence of 20ng/ml of recombinant
GM-CSF for nine days as previously described [11] and activated
with 0.1μg/ml LPS and 5ng/ml of GM-CSF for an additional 18
hours. A) Cells were stained for MHC class II, CD80, CD86 expression
with (open histogram) or without (grey histogram) LPS maturation
and analyzed by FACS.B) Cytokine concentrations in BMDC
supernatants were sampled after 18-hour culture with or without
LPS. C and D) To study the primary activation of Tg4 T cells, varying
numbers (as stated) of AMK35 [7] BMDC were cultured with 2x10
4
CD4+ Tg4.CD45.1+ T cells [12] per well. Cell proliferation was
assessed by thymidine incorporation. The results are expressed as
mean counts per minute ± standard error of the mean. Tg4 T cell
production of cytokines (IL-2, IL-17A, GM-CSF, TNF-α and IFN-γ) was
assessed in culture supernatants by ELISA. IL-2 was measured in
supernatants after 48 hours of culture and IFN-γ, TNF-α, GM-CSF and
IL-17A were measured after 72 hours of culture. Data are
representative of four independent experiments. BMDC, bone
marrow-derived dendritic cells;FACS, fluorescence activated cell
sorting; GM-CSF, granulocyte-macrophage colony-stimulating factor;
LPS, lipopolysaccharide; MBP, myelin basic protein.
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the in vitro proliferation of naïve Tg4 CD4+ T cells
(Figure 1C), and their production of IFN-γ, IL-17, TNF-
α and GM-CSF (Figure 1D), without any addition of
exogenous antigen to the culture. Thus, LPS-activated
DC appeared to have many of the key attributes asso-
ciated with EAE pathology. To test this in vivo, we
seeded C57BL/6xB10.PL mice with a cohort of naïve
Tg4 CD4+ T cells and one-day later subcutaneously
administered LPS-activated AMK35 DC. Ten out of 12
mice developed clinical signs of EAE (Figure 2A).
However, the extent and, importantly, the timing of
onset of clinical signs showed variation.
The use of BMDC derived from mice in which antigen
presentation is driven by a transgene, of course, has lim-
itations. For example, it can be envisaged that it would
be desirable to study DC expressing multiple autoanti-
genic peptides, either separately or together. To extend
our study in this direction we therefore generated
BMDC from AU+ non-transgenic BMDC, from B10.PL
mice. These BMDC were activated with LPS and loaded
with the Ac1-9(4Tyr) peptide in vitro. This variant pep-
tide binds to the Au molecule with high affinity, allowing
stable antigen presentation (unlike the wild type Ac1-9
peptide). These antigen-loaded non-transgenic DC could
efficiently activate naïve Tg4 T cells in vitro (Figure 2B)
and induced a robust disease course in the T cell/DC
transfer model in C57BL/6xB10.PL mice (Figure 2B). Of
note, there was a trend for the onset of disease to be
earlier and more synchronous than achieved with
AMK35 DC (Figure 2C).
The two novel models of DC-driven EAE we have
described have a number of advantages over the few
earlier reports of EAE following transfer of autoantigen-
loaded DC. Previous studies using BMDC pulsed with
the 35–55 peptide of myelin oligodendrocyte glycopro-
tein (MOG) in C57BL/6 mice have required repeated
injections of BMDC to induce EAE [3] or have required
concurrent administration of CFA to drive robust disease
[5]. A previous report of EAE involving MBP-pulsed DC
differed markedly from ours in that five times as many
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Figure 2 MBP loaded BMDC can initiate EAE in mice seeded
with MBP-reactive T cells. BMDC were generated from AMK35 or
B10.PL mice and matured with LPS as described in Figure 1.
A total of 2x106 Tg4.CD45.1 CD4+ T cells was transferred into B10.
PLxC57BL/6 mice one day prior to s.c. injection of 2x106
LPS-conditioned AMK35 BMDC (A) or B10.PL BMDC pulsed with
0.1μM MBP Ac1-9(4Tyr) analog peptide (B). of Pertussis toxin was
administered (200 ngi.p.) at the time of BMDC transfer. Clinical signs
of EAE were assessed daily with the following scoring system: 0, no
signs; 1, flaccid tail; 2, impaired righting reflex and/or gait; 3, partial
hind limb paralysis; 4, total hind limb paralysis; 5, hind limb paralysis
with partial front limb paralysis; 6, moribund or dead. A) Plots show
maximal clinical scores of mice administered AMK35 BMDC and the
clinical disease curve of three pooled, independent experiments.
B) A total of 2x104 Tg4 CD4+ T cells was cultured with LPS-
conditioned B10.PL BMDC pulsed with 0.1μM MBP Ac1-9(4Tyr) and
assessed for proliferation (thymidine incorporation). Plots show
maximal clinical scores of mice administered B10.PL BMDC pulsed
with 0.1μM MBP Ac1-9(4Tyr) and the clinical disease curve of three
pooled, independent experiments. C) Plot showing timing of disease
onset in mice administered AMK35 DC (black line, n=12) and MBP
Ac1-9(4Tyr) pulsed DC (dashed line, n=20). All mice were bred under
specific pathogen-free conditions at the University of Edinburgh and
all experiments had local ethical approval and were performed in
accordance with UK legislation. BMDC, bone marrow-derived
dendritic cells; DC, dendritic cells; EAE, experimental autoimmune
encephalomyelitis; LPS, lipopolysaccharide; MBP, myelin basic
protein.
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MBP-reactive T cells were transferred and the host mice
were irradiated prior to cell transfer [4]. Of note, the wild
type MBP peptide (lacking the insertion of a Tyr residue
at position 4) has such low affinity for Au that APC can-
not be pulsed with that peptide to allow efficient loading
into the Au peptide binding groove [13]. It is therefore
difficult to reconcile that observation with the reported
ability of DC loaded with the wild type peptide to activate
MBP-responsive T cells for the initiation of EAE [4]. Un-
like that previous report, we used two systems in which
the presentation of the autoantigenic peptide-MHC com-
plex by the DC was highly stable. AMK35 DC, expressing
transgenic peptide-MHC [7] induced variable degrees of
EAE, particularly in terms of day of onset, but this diffi-
culty was overcome using non-transgenic DC pulsed
with the Ac1-9(4Tyr) peptide, which shows extraordinary
affinity for the AU molecule [14]. DC that are loaded with
this peptide in vivo can maintain expression of the
peptide-MHC complex for at least seven days (SMA, un-
published). Given that the consensus is that BMDC prob-
ably persist for only a few days after administration, we
can be confident that the DC we transferred were pre-
senting the peptide to T cells for a sustained length of
time. It is conceivable that the MOG(35–55)-Ab com-
plex might be prone to more rapid degradation in DC
transfer experiments. Nevertheless, it is evident from
other studies that the use of MOG(35–55)-loaded
C57BL/6 DC can be sufficient to provide TCR-
signaling in vivo, as we ourselves have shown [15,16],
but it was not sufficient to trigger robust EAE, which
still required subsequent immunization with CFA in
those models.
A key paradigm is that autoreactive T cells can develop
into autoaggressive T cells if they recognize (self, or cross-
reactive non-self ) antigen presented during infection (that
is, on activated APC). The use of CFA to induce EAE
mimics infection due to the presence of heat-killed myco-
bacteria. However, CFA contains multiple moieties capable
of stimulating APC through a range of PRRs. Although
LPS is not one of these moieties, heat shock proteins 65
and 70 have been described as TLR-4 agonists [17], as has
pertussis toxin [18], which is routinely used during EAE
induction. Less complex adjuvants, including LPS, have
been reported to be able to substitute for CFA [19-22], but
results have been variable between studies. Indeed, expos-
ure to LPS can protect against EAE if it occurs before
immunization with autoantigen in CFA [23]. Those stud-
ies have not provided clear information on which APC
need to be activated through a given PRR to drive
pathology, or which of the multiple consequences of
PRR-ligation are non-redundant for the induction of
EAE. Furthermore, it is clear that expression of the
same TLR on different immune cells can have mark-
edly different effects on disease outcome [24,25].
From our experiments described here, we can con-
clude that a) DC are sufficient as APC to effectively
drive the differentiation of naïve myelin-responsive T
cells into autoaggressive effector T cells and b) exposure
to a TLR-4 agonist can activate the DC sufficiently to
deliver the signals required to drive the pathogenic func-
tion of the T cell. These new model systems will there-
fore allow comparison of a range of PRR stimuli upon
the DC and the use of gene-knockout/knockdown DC
to help to probe the key molecular events in the initial
DC-T cell dialogue that lead ultimately to autoimmune
CNS inflammation in EAE.
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